Adc Therapeutics SA risk profile
62 Stretched several inputs deteriorating together
Measured 21 October 2026 from ADCT's filed statements. Recomputed nightly.
62 (Stretched), driven by Cash conversion at 100, over 7 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 81 | Acute | Volatile | One-year price volatility — 97.0% |
| Operating pressure | 2 | Contained | Stable | Operating-margin drift — +15.3 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.00x |
| Leverage and coverage | 36 | Normal | Stable | Interest cover — -1.71x |
| Competitive position | 67 | Stretched | Stable | Operating-margin gap against peers — -137.5 percentage points |
| Concentration | 89 | Acute | Stable | Geographic concentration — 8,265 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Adc Therapeutics SA